Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Phase 1
25
about 1.4 years
18–65
1 site in MD
About this study
This trial is testing a treatment called fostamatinib in people with stable sickle cell disease. The goal is to see if this drug is safe and well-tolerated at different doses. Participants will take the drug twice daily for up to 6 weeks, and their health will be monitored through regular clinic visits.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Fostamatinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
fostamatinib
oral (Oral Tablet)
Primary: The number of type, incidence, severity and relationship to study treatment of adverse events and serious adverse events
Secondary: Number of participants that discontinued fostamatinib due to adverse events following CTCAE.